Literature DB >> 26866350

Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis.

Serge J Zweers1, Alexey Shiryaev2,3,4, Mina Komuta5, Mette Vesterhus2,6, Johannes R Hov2,3,4,7, María J Perugorria8, D Rudi de Waart1, Jung-Chin Chang1, Shanna Tol9, Anje A Te Velde1, Wouter J de Jonge1, Jesus M Banales8, Tania Roskams5, Ulrich Beuers1,10, Tom H Karlsen2,3,4,7, Peter L Jansen1,10,11, Frank G Schaap1,11.   

Abstract

BACKGROUND & AIMS: To better understand the pathogenesis of primary sclerosing cholangitis, anti- and pro-inflammatory factors were studied in bile.
METHODS: Ductal bile of PSC patients (n = 36) and controls (n = 20) was collected by endoscopic retrograde cholangiography. Gallbladder bile was collected at liver transplantation. Bile samples were analysed for cytokines, FGF19 and biliary lipids. Hepatobiliary tissues of PSC and non-PSC patients (n = 8-11 per patient group) were collected at transplantation and were analysed for IL8 and FGF19 mRNA expression and IL8 localization. The effect of IL8 on proliferation of primary human cholangiocytes and expression of pro-fibrotic genes was studied.
RESULTS: In PSC patients, median IL8 in ductal bile was 6.6 ng/ml vs. 0.24 ng/ml in controls. Median IL8 in gallbladder bile was 7.6 ng/ml in PSC vs. 2.2 and 0.3 ng/ml in two control groups. IL8 mRNA in PSC gallbladder was increased and bile ducts stained positive for IL8. In vitro, IL8 induced proliferation of primary human cholangiocytes and increased the expression of pro-fibrotic genes.
CONCLUSION: Elevation of IL8 in bile of PSC patients, collected at different stages of disease, indicates an ongoing inflammatory stimulus that drives IL8 production. This challenges the idea that advanced PSC is a burned-out disease, and calls for reconsideration of anti-inflammatory therapy in PSC.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bile; gallbladder; interleukin 8; primary sclerosing cholangitis

Mesh:

Substances:

Year:  2016        PMID: 26866350     DOI: 10.1111/liv.13092

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  12 in total

1.  Activated cholangiocytes release macrophage-polarizing extracellular vesicles bearing the DAMP S100A11.

Authors:  Tomohiro Katsumi; Maria Eugenia Guicciardi; Adiba Azad; Steven F Bronk; Anuradha Krishnan; Gregory J Gores
Journal:  Am J Physiol Cell Physiol       Date:  2019-07-31       Impact factor: 4.249

Review 2.  Emerging concepts in biliary repair and fibrosis.

Authors:  Luca Fabris; Carlo Spirli; Massimiliano Cadamuro; Romina Fiorotto; Mario Strazzabosco
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-05-19       Impact factor: 4.052

Review 3.  Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium.

Authors:  Mario Strazzabosco; Romina Fiorotto; Massimiliano Cadamuro; Carlo Spirli; Valeria Mariotti; Eleanna Kaffe; Roberto Scirpo; Luca Fabris
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-25       Impact factor: 5.187

Review 4.  Mechanisms of bile acid mediated inflammation in the liver.

Authors:  Man Li; Shi-Ying Cai; James L Boyer
Journal:  Mol Aspects Med       Date:  2017-07-01

5.  Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis.

Authors:  Malgorzata Milkiewicz; Marta Klak; Agnieszka Kempinska-Podhorodecka; Anna Wiechowska-Kozlowska; Elzbieta Urasinska; Malgorzata Blatkiewicz; Ewa Wunsch; Elwyn Elias; Piotr Milkiewicz
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

6.  Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis.

Authors:  Michael Trauner; Yevgeniy Gindin; Zhaoshi Jiang; Chuhan Chung; G Mani Subramanian; Robert P Myers; Aliya Gulamhusein; Kris V Kowdley; Cynthia Levy; Zachary Goodman; Michael P Manns; Andrew J Muir; Christopher L Bowlus
Journal:  JHEP Rep       Date:  2019-12-05

7.  Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.

Authors:  Nisanne S Ghonem; Adam M Auclair; Christopher L Hemme; Gina M Gallucci; Randolph de la Rosa Rodriguez; James L Boyer; David N Assis
Journal:  Clin Pharmacol Ther       Date:  2020-07-17       Impact factor: 6.875

8.  Metabolomic Profiling of Portal Blood and Bile Reveals Metabolic Signatures of Primary Sclerosing Cholangitis.

Authors:  Pamela S Tietz-Bogert; Minsuk Kim; Angela Cheung; James H Tabibian; Julie K Heimbach; Charles B Rosen; Madhumitha Nandakumar; Konstantinos N Lazaridis; Nicholas F LaRusso; Jaeyun Sung; Steven P O'Hara
Journal:  Int J Mol Sci       Date:  2018-10-16       Impact factor: 5.923

Review 9.  Treatment of primary sclerosing cholangitis in children.

Authors:  Trevor J Laborda; M Kyle Jensen; Marianne Kavan; Mark Deneau
Journal:  World J Hepatol       Date:  2019-01-27

10.  A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis.

Authors:  Yevgeniy Gindin; Chuhan Chung; Zhaoshi Jiang; Jing Zhu Zhou; Jun Xu; Andrew N Billin; Robert P Myers; Zachary Goodman; Abdolamir Landi; Michael Houghton; Richard M Green; Cynthia Levy; Kris V Kowdley; Christopher L Bowlus; Andrew J Muir; Michael Trauner
Journal:  Hepatology       Date:  2021-02-28       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.